Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 12
GLP-1 skin reactions: what two cases show
Two case reports link GLP-1 medicines to unusual skin reactions. Here is what they observed, and why they cannot establish risk or causation.
Low-Dose Tirzepatide in Japanese Care
A Japanese real-world study found lower HbA1c and BMI after 24 weeks of low-dose tirzepatide, with important design limits.
Oral semaglutide and water intake
A new oral semaglutide paper examines water measurement during simulated administration. Here is what the record and current label support.
Retatrutide Phase 3 Obesity Results
A Phase 3 trial reports retatrutide reduced mean body weight by 25.0% at 80 weeks in its highest-dose group versus placebo.
Semaglutide, CKD and Australia
An Australian panel places semaglutide's FLOW kidney results within shared care for type 2 diabetes and chronic kidney disease.
Tirzepatide heart risk after 1 year
A Mayo Clinic observational study links one year of tirzepatide use with improved risk markers, not proven prevention of cardiovascular events.
Tirzepatide and muscle loss: what we know
Tirzepatide weight loss includes fat and lean mass changes. Here is what body composition research can, and cannot, tell you.
Tirzepatide vs semaglutide: indirect data
A 2026 analysis compared SURMOUNT-1 with STEP 1. Tirzepatide 10 mg and 15 mg were associated with greater weight reduction, but this was not a new trial.
GLP-1 Gut Side Effects: What a Review Found
A narrative review summarizes gastrointestinal effects of GLP-1 and dual GIP/GLP-1 medicines and the limits of class-wide claims.
Novo's Hengrui Obesity-Pill Deal Explained
Novo has licensed an early-stage oral obesity candidate from Hengrui. Here is what the deal does and does not show.
TRIUMPH-2: Retatrutide at 80 Weeks
TRIUMPH-2 found greater weight loss with retatrutide than placebo at 80 weeks in adults with obesity and type 2 diabetes.
Semaglutide and inflammatory monocytes
A 16-person study linked semaglutide with lower inflammatory monocytes and bone-marrow imaging changes, but it cannot prove cause and effect.